Who founded Transition Bio?

Transition Bio was founded by Tuomas Knowles, Samuel Cohen, G. Kelly Martin in 2020.

Who are Transition Bio's investors?

Transition Bio's investors include Northpond Ventures, Lifeforce Capital, Magnetic Ventures, Taiho Ventures, LLC, Dolby Family Ventures.

How much funding has Transition Bio raised?

Transition Bio has disclosed $58.4M raised across 3 rounds.

Where is Transition Bio headquartered?

Transition Bio is headquartered in Cambridge, US.

Transition Bio

Cambridge, US · Founded 2020 · Delaware corporation · 5 known investors

Find your way into Transition Bio

1,224 people in our graph share verified history with the Transition Bio team — schools, employers, funds. One of them is your warm intro.

Chris Bischoffunlockedknows Samuel Cohen · together at Goldman Sachs (overlapped)

×7knows the team · via University of Cambridge

knows the team · via Harvard University

×3knows the team · via Goldman Sachs

Transition Bio applies methods from physics, chemistry, biology, and machine learning to study protein biophysics—including protein aggregation, self-assembly, and protein-protein interactions—for developing therapeutics targeting health and disease. The company is a platform-based biotherapeutics developer founded on academic research from the University of Cambridge.

AI & Machine Learning Biotech Deep Tech

Founders & leadership

Transition Bio was founded in 2020 by Tuomas Knowles, Samuel Cohen, and G. Kelly Martin.

Tuomas KnowlesExecutive Director, Co-Founder & Chief Technology Officer

Samuel Cohen inExecutive Director & Co-FounderSamuel Cohen is co-founder and Executive Director of Transition Bio, a platform-based biotherapeutics company applying physics, chemistry, and machine learning to protein biophysics. He previously co-founded Ride Therapeutics and has a background as a research scientist with extensive publications, alongside experience in venture capital and strategy consulting.

G. Kelly MartinExecutive Chairman & Co-Founder

George MartininExecutive

Stephanie Torruella inExecutiveStephanie Torruella is Executive Officer at Transition Bio, a platform-based biotherapeutics developer using computational and experimental methods to study protein biophysics for drug development.

Preet MakkarExecutive

Martin KulanderNamed on SEC filing

Gregory L. MillerNamed on SEC filing

Board

Robert WeeksBoard director

Paxton Major inBoard directorManaging Director at Northpond Ventures

Connor McDermottinBoard directorAssociate at Northpond Ventures

Kathy YiBoard director

Investors · 5

Northpond Ventures✓ verifiedBethesda · $100K – $5M

Lifeforce CapitalChevy Chase · $500K – $5M

Magnetic VenturesBoston · $1M – $6M

Taiho Ventures, LLCMenlo Park

Dolby Family VenturesreportedSan Francisco

Reported raises · per SEC filings

Form D private placements

$58.4M disclosed across 3 rounds · 2022–2024

▶$13.3MraisedOct 2024 · 8 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Tuomas KnowlesDirector
Kathy YiDirector
Robert WeeksDirector
George MartinExecutive Officer, Director
Al SandrockDirector
Stephanie TorruellaExecutive Officer
Samuel CohenDirector
Preet MakkarExecutive Officer
Paxton MajorDirector

Offering amount: $21.3M
Amount sold: $13.3M
First sale: Oct 2024
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$6MraisedJan 2024 · 5 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Samuel CohenDirector
Connor McDermottDirector
Tuomas KnowlesExecutive Officer, Director
George MartinExecutive Officer, Director
Preet MakkarExecutive Officer
Kathy YiDirector
Stephanie TorruellaExecutive Officer
Al SandrockDirector

Offering amount: $15M
Amount sold: $6M
First sale: Dec 2023
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$39.1MraisedMar 2023 · 22 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Kathy YiDirector
Samuel CohenDirector
George K. MartinDirector
Martin KulanderExecutive Officer
Connor McDermottDirector
Tuomas KnowlesExecutive Officer
Gregory L. MillerExecutive Officer, Director
Al SandrockDirector

Offering amount: $50M
Amount sold: $39.1M
First sale: Mar 2022
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Northpond Ventures-Backed Transition Bio Raises $13.3M | citybizcitybiz.co · Oct 2024

Transition Bio closes funding to find biomolecular condensatescen.acs.org · Jun 2022

Joint Harvard-Cambridge spin-out closes $50m Series A to drive biomolecular condensate drug discovery – Cambridge Enterpriseenterprise.cam.ac.uk · Jun 2022

Transition Bio Closes $50 Million Series A Financing to Accelerate Biomolecular Condensate Drug Discoverybusinesswire.com · Jun 2022

Transition Bio Closes $50M Series A Financing - FinSMEsfinsmes.com · Jun 2022

Transition Bio Funding: $76.5M | Complete Analysis | Extruct AIextruct.ai

Frequently asked questions

What does Transition Bio do?: Transition Bio applies methods from physics, chemistry, biology, and machine learning to study protein biophysics—including protein aggregation, self-assembly, and protein-protein interactions—for developing therapeutics targeting health and disease. The company is a platform-based biotherapeutics developer founded on academic research from the University of Cambridge.
Who founded Transition Bio?: Transition Bio was founded by Tuomas Knowles, Samuel Cohen, G. Kelly Martin in 2020.
Who are Transition Bio's investors?: Transition Bio's investors include Northpond Ventures, Lifeforce Capital, Magnetic Ventures, Taiho Ventures, LLC, Dolby Family Ventures.
How much funding has Transition Bio raised?: Transition Bio has disclosed $58.4M raised across 3 rounds.
Where is Transition Bio headquartered?: Transition Bio is headquartered in Cambridge, US.